Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjuvant immunotherapy for melanoma.

L J Humphrey, S Taschler-Collins, P M Goldfarb

    Journal of Surgical Oncology
    |April 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The role of intratumour therapy with electroporation and bleomycin in the management of advanced squamous cell carcinoma of the head and neck.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2005
    Same author

    Is homeopathy incompatible with evidence-based medicine?

    Archives of internal medicine·2000
    Same author

    Treated ovarian cancer: comparison of MR imaging with serum CA-125 level and physical examination--a longitudinal study.

    Radiology·1999
    Same author

    The credentialing of American surgery.

    Annals of surgical oncology·1997
    Same author

    Physical therapy.

    The Journal of the Kentucky Medical Association·1997
    Same author

    High mortality after abdominal operation in patients with large-volume malignant ascites.

    Journal of surgical oncology·1996
    Same journal

    Comparative Analysis of CEM and Breast MRI: A Retrospective Study.

    Journal of surgical oncology·2026
    Same journal

    The Treatment Efficacy for Patients Undergoing Combined Transanal-Transabdominal Endoscopic Resection of Rectal Anastomosis Stenosis.

    Journal of surgical oncology·2026
    Same journal

    "It Depends on the Situation": Variability in How Surgical Oncologists Elicit and Integrate Patient Values.

    Journal of surgical oncology·2026
    Same journal

    A Tale of Two Pathways: Same-Surgeon Versus Different-Surgeon Resection After Second Surgical Opinion.

    Journal of surgical oncology·2026
    Same journal

    How I Do It: The Life and Work of a Rubber Band in Robotic Liver Parenchymal Transection.

    Journal of surgical oncology·2026
    Same journal

    New Paradigms of Cancer Require New Language: A Qualitative Study Exploring Language for Non-Curative Non-Palliative Cancer Surgery.

    Journal of surgical oncology·2026
    See all related articles

    Adjuvant immunotherapy improved survival rates in melanoma patients. This study observed enhanced projected 5-year survival for both lymph-node-negative and lymph-node-positive melanoma cases.

    Area of Science:

    • Oncology
    • Immunology
    • Melanoma Research

    Background:

    • Melanoma treatment often involves adjuvant therapies post-surgery.
    • Immunotherapy aims to stimulate the patient's immune system against cancer cells.

    Purpose of the Study:

    • To evaluate the efficacy of adjuvant immunotherapy in melanoma patients.
    • To assess projected and observed survival rates following treatment.

    Main Methods:

    • Administered adjuvant active specific homologous cell protein preparation immunotherapy.
    • Treated 84 lymph-node-negative and 25 lymph-node-positive melanoma patients.
    • Followed patients for over 2 years post-surgery.

    Main Results:

    • Projected 5-year survival rates exceeded expected outcomes across stages.

    Related Experiment Videos

  • Stage I melanoma patients showed a 90% projected 5-year survival.
  • Stage II melanoma patients had a 68% projected 5-year survival.

    • Conclusions:

    • Adjuvant immunotherapy demonstrated improved survival in melanoma patients.
    • The observed survival rates suggest a beneficial effect of the immunotherapy regimen.
    • Further randomized studies are warranted to confirm these findings.